Targeting NMDA receptors in neuropsychiatric disorders by drug screening on human neurons derived from pluripotent stem cells

Wenbo Zhang, P. Joel Ross, James Ellis and Michael W. Salter

© The Author(s) 2022

INTRODUCTION

Neuropsychiatric disorders, such as epilepsy, intellectual disability (ID), autism spectrum disorder (ASD), and schizophrenia, are complex brain disorders and cause a heavy burden on individuals, family, and society because of the prevalence, life-long course, and few efficacious medications [1–3]. The molecular basis of neuropsychiatric disorders remains incompletely understood, and genetic factors have key roles in the occurrence of these disorders [3, 4]. The imbalance between excitation and inhibition in neural circuits contributes to the pathogenesis and development of various neuropsychiatric disorders [5]. NMDA receptor (NMDAR)-mediated neurotransmission plays a crucial role in maintaining the balance between neural excitation and inhibition in the mammalian central nervous system (CNS) [6]. Dysfunction of NMDARs, which may lead to the imbalance between excitation and inhibition, has been widely reported in neuropsychiatric disorders including epilepsy, ID, ASD, and schizophrenia [7, 8]. NMDARs are therefore increasingly important targets for the discovery and development of drugs. Currently, there are few effective and safe medications for treating neuropsychiatric disorders, and efforts to develop drugs for brain disorders face many challenges [9–11]. The absence of efficacious medications is attributed, in part, to limitations and a shortage of animal models for preclinical studies on the discovery and development of drugs.

Induced pluripotent stem cells (iPSCs) generated by reprogramming human somatic cells have been broadly used since 2008 and afford an efficient model system for disease modeling, toxicity screens, and screening for novel therapeutics because of their genetic relevance to individuals with the disease [12–16]. The neurons derived from human iPSCs have been utilized extensively in neuropsychiatric disorders to probe the molecular pathophysiology of these disorders, and to link molecular findings with clinical features to identify therapeutic targets [2, 12, 17–24]. For example, iPSC studies revealed that ezogabine (an anti-epileptic drug) corrected excitability impairments in a model of amyotrophic lateral sclerosis, leading to subsequent approval for clinical trial [25, 26].

Human iPSC-derived neurons provide a valuable and powerful platform for modeling NMDAR dysfunction associated with neuropsychiatric disorders and translational drug screening because of their relevance to human genetic background and physiology. Disease modeling in iPSCs does not require a priori knowledge of molecular pathways affected in specific neuropsychiatric disorders, and can be used to model effects of variants in specific risk genes or the polygenic risk associated with particular genotypes. Human neurons are advantageous for modeling effects of gene regulatory variants, whose functions may not be
conserved between humans and animal models [27, 28]. The expression and importance of human-specific genes in the brain, some of which have been found to be differentially expressed in human iPSC-derived neurons, support the need to use human neurons in investigating neuropsychiatric disorders in combination with mouse models [27]. A recent study reported that a short GluN2A-NMDAR isoform is expressed in brain tissue specifically from human and primate but not rodent [29]. These findings indicate that the human iPSC-derived neuron-based model may be a powerful platform to investigate NMDARs. iPSCs are also powerful for modeling disorders of the brain because they can be differentiated into a wide range of neuronal and non-neuronal subtypes, which can be purified and/or co-cultured in controlled environmental conditions [30]. However, there are challenges to utilize human iPSC-derived neurons for modeling neuropsychiatric disorders, such as relative immaturity of the neurons and delayed development of functional NMDARs [12, 19, 28, 31–33]. It is therefore important to overcome these challenges for utilizing these human neurons for the discovery and development of drugs targeting NMDARs.

DYSFUNCTION OF NMDARS ASSOCIATED WITH NEUROPSYCHIATRIC DISORDERS

NMDARs, a subtype of ionotropic glutamate receptor, are heterotetrameric cation channels (Fig. 1). The channels contain two obligatory GluN1 subunits with co-agonist glycine binding sites. They also contain two GluN2 subunits with glutamate binding sites, or one GluN2 subunit and one GluN3 subunit [6, 34]. The GluN1 subunits are expressed as eight distinct splice variants encoded by a single GRIN1 gene, whereas there are four GluN2 subunits (GluN2A-D) encoded by four different GRIN2 genes [6]. Genetic association studies have identified the biological linkage of hundreds of genetic risk loci with neuropsychiatric disorders, but genetic causal associations in most of these disorders have not been firmly established [4]. However, specific genetic variants associated with dysfunction of NMDARs are implicated in various neuropsychiatric disorders and are widely considered to be one of the molecular bases of the prevalent comorbidities among many of these disorders [7, 8, 35–38]. Dysfunction of NMDARs may result from genomic variations in any of the genes that encode the receptor subunits, but disease-associated variants have been identified primarily in GRIN1, GRIN2A, and GRIN2B [7, 8, 39, 40]. Variants of GRIN2C-D and GRIN3A-B have also been reported in neuropsychiatric disorders [7, 8, 39]. Reported disease-associated variants of NMDAR subunits include missense, nonsense, frameshift, splice site, and others.

The consequence of these alterations of NMDARs on receptor function and neuronal function is complicated. First, functional analysis shows that these identified genomic variations of NMDARs cause a wide range of changes in NMDAR properties, including potency of agonist/co-agonist, single-channel conductance, receptor kinetics, Ca2+ permeability, and pharmacological properties [6, 8]. Second, these variant NMDARs can exhibit hyperfunction (gain of function), hypofunction (loss of function) or no change in function of the receptors in neuropsychiatric disorders. Interestingly, different types of NMDAR dysfunction may cause similar phenotypes in neuropsychiatric disorders, possibly due to compensatory mechanisms [8]. Some variants of NMDARs occur at the same residue position but cause different types of neuropsychiatric disorders [7, 8]. Finally, genetic variants in other risk genes of neuropsychiatric disorders or other factors can indirectly cause dysfunction of NMDARs as a downstream consequence [41–46]. Here, we outline the dysfunction of NMDARs in neuropsychiatric disorders, and use epilepsy, ID, ASD and schizophrenia as examples to discuss the dysfunction of the receptors.
Dysfunction of NMDARs associated with neuropsychiatric disorders

**NMDAR dysfunction in epilepsy.** Epilepsy is one of the most common neurological conditions and affects people of all ages [47]. Epilepsy is characterized by unprovoked epileptic seizures, including focal seizures and generalized seizures, due to abnormal electrical activity in neurons, which can cause other health issues in cognition, psychology, and social skills [48]. In addition to clinical features, seizure onset can be confirmed by examining results from electroencephalography and neuroimaging. Alterations in NMDARs, which result in a change in the balance between neural excitation and inhibition, are important cellular events in the pathogenesis of epileptic seizures [7]. Epilepsy-associated variants in NMDAR subunits, including GRIN1 gene encoding GluN1 subunits and GRIN2(A-D) gene encoding GluN2(A-D) subunits, respectively, have been reviewed in detail [8, 49, 50].

In various neuropsychiatric disorders, over 70% of the individuals with GRIN2A variants are diagnosed with epilepsy, whereas less than 30% of the individuals with GRIN2B variants have epilepsy [7, 8]. The distinct roles of GluN2A and GluN2B in neuropsychiatric disorders may be attributed to the properties of GluN2 subunits in determining the receptor deactivation kinetics, channel gating, Ca$^{2+}$ permeability, and voltage-dependent blockade by extracellular Mg$^{2+}$ [6].

Epilepsy-associated variants in NMDAR subunits have complicated functional consequences, including hyperfunction, hypofunction, and no change in function of the receptors [8, 49]. How such changes in NMDAR function relate to the pathogenesis of epilepsy remains poorly understood.

**NMDAR dysfunction in ID.** ID is a type of neurodevelopmental disorder, a large group of early onset disorders, characterized by deficits in cognitive abilities [51]. In addition to learning disabilities, individuals with ID may have facial features and autistic behavior. Genetic variants are believed to have key roles in the pathogenesis of neurodevelopmental disorders including ID [51], and studies have indicated that variant NMDARs are risk factors for these disorders, implying dysfunction of the receptors in their etiology [7, 8].

GRIN1 and GRIN2 variants of NMDARs are implicated in the pathophysiology of ID. However, different from those in epilepsy, GRIN2B but not GRIN2A variants are mostly associated with ID [8]. In various neuropsychiatric disorders, over 80% of the individuals with GRIN2B variants are diagnosed with ID.

**NMDAR dysfunction in ASD.** ASD is a complex neurodevelopmental disorder with cranio-facial characteristics, impairment in social interactions, verbal and non-verbal communication, and restricted, repetitive behavior [51]. Genetic variants of GRIN1 and GRIN2 have been implicated in the pathophysiology of ASD, and GRIN2B variants are primarily associated with ASD [8]. In various neuropsychiatric disorders, approximately 30% of the individuals with GRIN2B variants are diagnosed with ASD.

Alternative splicing of NMDAR GluN1 subunits has been implicated in pathophysiology of ASD [52–54]. The GluN1 subunits have eight distinct isoforms, GluN1(1a-4a) and GluN1(1b-4b). The GluN1-b isoforms contain an additional 21 amino-acid sequence, known as the N1 cassette, in an extracellular amino-terminal region of the subunit proteins [6]. The presence or absence of the N1 cassette affects the function and pharmacology of NMDARs [6, 52]. Studies in post-mortem samples of cortex and human iPSC-derived neurons from individuals with ASD have implicated a decrease in expression of GRIN1-b isoforms, which contain the N1 cassette [52–54].

In addition, ASD-associated variants of other genes may cause dysfunction of NMDARs through protein-protein interactions, as an important pathophysiological process in the occurrence of the disorders. These genes include NLGN, which encodes the protein neuroligins [55–58], and SHANK genes, which encode post-synaptic scaffolding proteins of the SHANK family [59–63]. Autism-associated disruption of the long noncoding RNA, PTCHD1-AS, leads to dysfunction of NMDARs [64].

**NMDAR dysfunction in schizophrenia.** Schizophrenia is a major, chronic psychiatric disorder and is characterized by hallucinations, disorganized thoughts, cognitive dysfunction, and attention and social deficits [65]. Schizophrenia is a highly heritable psychiatric disorder and has a genetic origin, with a high prevalence of approximately 1% of the population worldwide [65]. Genome-wide association studies have provided insights into numerous risk genes for schizophrenia implicating the protein products in the pathogenesis of this severe psychiatric disorder [66–70]. Variants in NMDAR subunits, which cause hypofunction of NMDARs, have been implicated in the pathophysiology of schizophrenia [7, 8, 66, 70–75].

Before the surge of genetic evidence supporting the association of NMDAR malfunction with schizophrenia, hypofunction of NMDARs in the pathogenesis of schizophrenia was originally identified from observations on the psychotomimetic effects of non-competitive NMDAR antagonists. These antagonists including phencyclidine- and ketamine-induced symptoms similar to those of human subjects with schizophrenia [76].

In addition, hypofunction of NMDARs has been reported in schizophrenia due to alterations in signaling pathways through NMDAR-interacting proteins such as neuregulin-ErbB receptors [42, 43, 77], disrupted-in-schizophrenia 1 (DISC1) [44, 78], calci-neurin [79], and a7 nicotinic acetylcholine receptors [45, 80].

**Screening of drugs targeting NMDARs in neuropsychiatric disorders.** Complicated consequences on NMDAR function including hyperfunction, hypofunction, and no change in function, which are caused by genetic variants of these receptors in neuropsychiatric disorders such as epilepsy, ID, ASD, and schizophrenia, lead to the need for specific drugs targeting these receptors for treating these disorders. Thus, a mechanism-based approach, screening of specific drugs targeting NMDARs, could be advantageous for novel therapeutics in neuropsychiatric disorders, and human iPSC-derived neurons can provide an unprecedented system for modeling these disorders and the screening.

**Challenges of human iPSC-derived neurons in modeling neuropsychiatric disorders.** Human iPSC-derived neuron-based disease models are a promising strategy for identifying novel therapeutics because they are genetically matched to individuals with neuropsychiatric disorders [81, 82], and therefore provide a unique opportunity as a translational screening platform for the discovery and development of drugs targeting NMDARs. In addition, human iPSC-derived neuron-based model is a promising strategy for neurotoxicity screening. Human iPSC-derived neurons have biological and physiological relevance to human primary neurons and thus provide a valuable and powerful platform for neuronal toxicity studies by improving the accuracy of screening for therapeutic compounds as well as decreasing the cost and time-consuming in pre-clinical trials [83]. Despite advantages in disease modeling, studies also revealed the presence of challenges to utilize human iPSC-derived neurons for modeling neuropsychiatric disorders, which include a relatively immature feature of the neurons, variation between iPSC lines, neuronal density-induced variability, and very slow differentiation into functional neurons [12, 19, 28, 31–33].

Over the past decade, approaches for improving the maturation of these neurons have been explored. Rapid single-step neurogenin-2 (NGN2) induction accelerates the maturation of neurons directly converted from iPSCs without a stage of neural progenitor cells (NPCs), which mature in 3–4 weeks [84]. In addition, compared with conventional two-dimensional cell culture systems, three-
dimensional cell culture systems—brain organoids—may more closely mimic the environment of neurodevelopment in the mammalian CNS and thus improve the maturation of iPSC-derived neurons [85–87]. However, organoids show challenges and disadvantages such as experimental cost, technical issues for imaging and electrophysiology, and variability between batches [85, 88].

Maturation of human iPSC-derived neurons can be promoted through modifying culture environments. Co-culture with astrocytes accelerates functional maturation and synapse formation of human iPSC-neurons [89–94], and thus improves the efficiency for modeling neuropsychiatric disorders [18, 64, 95–97]. Functional maturation of human iPSC-derived neurons is also promoted by using culture media such as BrainPhys [98, 99]. In addition, nanoscale biophysical stimulation could promote the maturation of human iPSC-derived neurons through substrate nanotopography [100, 101].

Variability between cultures in neuronal density may affect neuronal and network characteristics. This may be at least partially controlled by co-culture of iPSC-derived cells from unaffected controls together with those from individuals with neuropsychiatric disorders [95, 97]. Such co-culture also helps to overcome the challenge of the effects of varying genetic background between cultures and, in addition, provides a chance to examine whether alterations are cell autonomous [95, 97, 102].

Another challenge associated with disease modeling in iPSCs is limited statistical sensitivity arising from variability and limited sample sizes [24, 28, 103]. Standard guidelines dictate that iPSC studies of brain disorders should include ≥2 affected individuals and ≥2 unaffected controls, with 2–3 clonal iPSC lines per person [24]. Numbers of iPSC lines are often limited by cost, time, or availability (particularly for rare disorders). When many donors are available, statistical power may be improved by increasing the number of individuals in the study at the expense of analyzing fewer iPSC clones per individual [103]. To overcome variability between donors, genome editing can be used to introduce targeted mutations in specific neuropsychiatric risk genes, and subsequent analyses of isogenic lines may also improve statistical sensitivity [24, 28, 103]. Other approaches to overcome variability include limiting variability between study participants by focusing on individuals with similar genetic variants (e.g., loss of function variants in GRIN2B), or individuals with defined phenotypic classifications (e.g., NMDAR hypofunction). Some experimental approaches like transcriptomics are particularly sensitive to heterogeneity, so computational tools have been developed to improve signal-to-noise ratio [104]. RNA deconvolution may be a potential method to eliminate transcriptomic variability in neural differentiation and maturation [91].

**Human NMDARs in situ in iPSC-derived neurons**

*Expression level of human NMDARs in situ.* Human iPSC-derived neurons progressively express functional NMDARs over time in culture (Fig. 2). The amplitudes of NMDA-evoked currents are substantial in neurons with about 8 weeks of differentiation in culture after the NPC stage, but synaptic NMDAR currents may be absent at this time and require even longer-term culture.
Comparison of NMDAR currents with AMPAR currents and other ion channel-mediated currents in the previously reported studies in human iPSC-derived neurons and in neurons in the human brain biopsy tissue.

| Authors | Year | Protocol | Weeks in culture | Neuron type | NMDAR mRNA Current (pA) | AMPAR mRNA Current (pA) | Na⁺ channel (pA) | K⁺ channel (pA) |
|---------|------|----------|------------------|-------------|-------------------------|-----------------------|------------------|----------------|
| Ross et al. [64] | 2020 | NPC | 8–16 | Mixed | −1000 | −600 | −600 | −500 |
| Zhang et al. [32] | 2016 | NPC | >7 | Mixed | −1000 | −400 | −520 | −530 |
| Shcheglovitov et al. [97] | 2013 | NPC | 5–6 | Mixed | −100 | −80 | −80 | −0 |
| Zhang et al. [84]b | 2013 | NGN2 | >2 | excitatory | −1000 | −400 | −75 | −75 |
| Lam et al. [108]c | 2017 | NGN2 | 2–6 | excitatory | −1000 | −70 | −70 | −50 |
| Neume et al. [107]d | 2018 | NGN2 | 3–7 | excitatory | −1000 | −70 | −70 | −50 |
| Pegasiou et al. [160] | 2020 | Human brain biopsy tissue | −100 | −75 | −75 | −75 | −75 | −75 |

Data displayed in this table are approximate values reported in the previously reported studies. If there are two rows from the same study, synaptic currents are displayed in the upper one and NMDA-evoked currents are displayed in the bottom one. Unless otherwise indicated, NMDAR currents and AMPAR currents were evoked by applying NMDA and AMPA, respectively, in human iPSC-derived neurons, which were differentiated through an NPC stage (NPC) or differentiated with a rapid single-step NGN2 induction (NGN2).

Subunit composition of human NMDARs in situ. mRNA expression of NMDAR subunits, including GRIN1, GRIN2(A-D), and GRIN3(A-B), has been probed in human iPSC-derived neurons [95, 112, 113]. Electrophysiological studies uncovered that GluN2A subunits mediate only 10–30% of NMDA-evoked currents, whereas GluN2B subunits mediate over 70% of these currents in both human iPSC-derived neurons differentiated through an NPC stage and in NGN2 neurons [32, 112, 114], suggesting that GluN2B subunits dominate NMDAR responses in these neurons. Furthermore, the decay time of NMDAR-mediated miniature excitatory postsynaptic current (mEPSCs) is beyond 250 ms [32], confirming that GluN2B subunits, which have much slower decay time kinetics than GluN2A subunits [6], are the dominant subtype of NMDAR in human iPSC-derived neurons. The subunit diversity of NMDARs determines the receptor properties and function in the physiological and pathological processes in the mammalian CNS [6]. The GluN2 subunits have differential expression and distribution in specific brain regions, neuronal types, and locations. Furthermore, NMDAR subunits, specifically GluN2A and GluN2B, display unique spatiotemporal expression patterns [6]. GluN2A and GluN2B dominate in the mammalian higher brain structures such as the cortex, and it is well known that there is a developmental switch for NMDAR GluN2 subunits during postnatal development [6], which leads to a change of NMDAR subunit composition from GluN2B to GluN2A subunit-dominant receptors in most brain regions including the cortex, particularly at synapses. This switch is evolutionarily conserved and related to synaptic maturation and learning formation [6]. Thus, the finding of GluN2B subunit-dominant NMDARs suggests that there is the delay of the developmental trajectory of NMDARs in human iPSC-derived neurons.

GluN2C subunits have not been detected at the protein level in human iPSC-derived neurons, whereas these neurons express GluN2D subunit proteins at a very low level, with no function [112]. Currently, there are no studies investigating NMDAR GluN3 subunit proteins or function in human iPSC-derived neurons.

Pharmacological properties of human NMDARs in situ. Human NMDARs in situ in iPSC-derived neurons have pharmacological properties similar to those of neurons in the mammalian CNS, such as voltage-dependent block by extracellular Mg²⁺, sensitivity to Zn²⁺, and blockade by TCN 201 and NVP-AAM077 of GluN2A antagonists and Ro 25-6981 and ifenprodil of GluN2B antagonists [32, 105, 112]. In addition, NMDAR currents are potentiated in human iPSC-derived neurons by GNE-9278, a selective, positive allosteric modulator of GluN2B subunits [112]. Moreover, NMDAR currents are upregulated by Fyn kinase, a member of the Src family of non-receptor tyrosine kinases, in human iPSC-derived neurons.

[32, 64, 97, 105, 106]. In human NGN2 iPSC-derived neurons, in which the NPC stage is skipped, NMDAR currents are tiny or undetected, although AMPA receptors, another major type of ionotropic glutamate receptor, are robustly expressed (Table 1) [84, 107, 108]. This contrasts to normal development of glutamatergic synapses, during which expression of NMDARs is prior to that of AMPA receptors and AMPA receptors are inserted into NMDAR-dominant excitatory synapses called “silent synapses” [109–111]. Thus, skipping the NPC stage in the induction of human NGN2 iPSC-derived neurons appears to cause a loss of a developmental window, thereby leading to decreased expression of NMDARs. In addition, human NGN2 iPSC-derived neurons express very large voltage-gated Na⁺ currents and voltage-gated K⁺ currents [84], reinforcing the limited expression of NMDARs in these neurons (Table 1). Extrasynaptic NMDAR currents in human NGN2 iPSC-derived neurons may be able to be enhanced through long-term culture, but even then, it is difficult to detect synaptic NMDAR currents [84, 107, 108].
neurons, as in the neurons from the rodent CNS [32, 115].

Thus, human iPSC-derived neuron-based models can be utilized for investigating NMDARs, and studies have uncovered the association of the receptor deficiency with neuropsychiatric disorders with this model [52, 64, 95, 97, 113, 116–119]. However, the delay of the developmental trajectory of NMDARs, such as low expression of GluN2A and limited synaptic localization of these receptors, may hamper the utilization in disease modeling and the discovery and development of drugs targeting NMDARs, especially for the receptor subtype-selective targeting.

**PROMOTING NEURONAL MATURATION AND ACCELERATING FUNCTIONAL EXPRESSION OF NMDARs IN HUMAN iPSC-DERIVED NEURONS**

Optimizing differentiation to promote maturation of human iPSC-derived neurons

We have learned a lot from studying animal models, in particular, that small molecules significantly accelerate neuronal differentiation in rodent primary neural cultures [120, 121]. In addition, small molecules promote the maturation of neurons derived from rodent embryonic stem (ES) cells, as well as from human ES cells [122–125]. These studies provide a strong basis for utilizing small molecules to promote the neuronal maturation of human iPSC-derived neurons [126–130].

Efforts using high-throughput screen for compounds with human iPSC-derived neurons have identified over 100 small molecules, including 37 approved drugs, which modulate neurite growth [131]. Combinatorial application of small molecules, including DAPT, PD0315901, SU5402, and CHIR99021, accelerated the induction of early-born, human iPSC-derived neurons with mature features including electrophysiological properties, and the resulting neurons were able to form long-distance projections in the postnatal mouse cortex after they were transplanted at 8 days of differentiation [128]. Azothymidine, an inhibitor of telomerase, improves differentiation and maturation of human iPSC-derived neurons [132]. Modulating gene expression is an alternative approach for improving the maturation of human iPSC-derived neurons. Expression of the transcription factor achaete-scute homolog 1 improves the maturation of human iPSC-derived neurons through increasing neurite length and numbers of branch points [133].

Facilitating functional expression of NMDARs in human iPSC-derived neurons

Thrombospondin-4 (TBP4) and SPARC-like protein 1 (SPARC1L), specific factors enriched in serum from young mice, improve synaptic connectivity of neurons differentiated from human ES cells [134]. In particular, SPARC1L but not TBP4 promotes functional expression of NMDARs and such improvement occurs specifically at excitatory but not inhibitory synapses [134, 135].

The developmental switch of NMDAR subunits from primarily GluN2B to GluN2A shapes synaptic plasticity and learning and memory formation [6]. The repressor element 1 silencing transcription factor (REST) can trigger the developmental switch of NMDAR GluN2 subunits in the hippocampus of neonatal rats [136], and cellular prion proteins are required for the REST-regulated developmental switch [137]. Furthermore, mIR-19a and mIR-539, two microRNAs which modulate gene expression post-transcriptionally, collaborate with REST and thus regulate the expression of NMDAR GluN2A and GluN2B subunits in rat primary neurons [138]. Homeodomain interacting protein kinase 2 (HIPK2) negatively regulates the expression of NMDAR subunit GluN2A and GluN2C and knockout of Hikp2 in the mouse brain increases the expression of GluN2A and thus the GluN2A/GluN2B ratio through altering JNK (c-Jun N-terminal kinase)–c-Jun signaling pathway [139]. In addition, the activity of histone deacetylase has a role in regulating the expression of GluN2B in rat cortical neurons and thus may have an effect on the developmental switch of NMDAR subunits and synaptic maturation [140].

**HUMAN iPSC-DERIVED NEURONS AS A TRANSLATIONAL SCREENING PLATFORM FOR THE DISCOVERY OF DRUGS TARGETING NMDARS**

Feasibility of using human iPSC-derived neurons for screening of drugs targeting NMDARs

Recent investigations have indicated the feasibility of using human iPSC-derived neurons for the discovery and development of drugs targeting NMDARs. High content imaging was utilized to measure the effect of compounds on neurite growth of human iPSC-derived neurons and approximately 100 out of 4421 bioactive small molecules were identified, which control neurite growth [131]. Such high content imaging may be a suitable approach to high-throughput screening of drugs modulating the expression of NMDARs in human iPSC-derived neurons.

The permeability to Ca$^{2+}$, as well as to monovalent cations like Na$^+$ and K$^+$, allows Ca$^{2+}$ imaging to be a reliable, but indirect method to measure NMDAR function, and high content imaging-based analysis of intracellular Ca$^{2+}$ dynamics can evaluate NMDAR-mediated Ca$^{2+}$ signaling for identifying drugs targeting the receptors. Another approach to investigate NMDAR function is the use of microelectrode arrays (MEA), which record neuronal spiking activity extracellularly. Monitoring the level of intracellular Ca$^{2+}$ and MEA provide powerful, high-throughput approaches to examine neural circuit activity. Ca$^{2+}$ imaging [147] and MEA [113] have been successfully utilized in human iPSC-derived neurons for readout of NMDAR function through evaluating Ca$^{2+}$ signaling and contribution of synaptic transmission to network activity. However, Ca$^{2+}$ imaging and MEA as indirect approaches, have limitations on examining NMDAR function, particularly on
pharmacological studies on NMDARs. To overcome the limitations, promising compounds identified using these approaches can then be tested using whole-cell patch-clamp electrophysiology for directly exploring the molecular mechanisms underlying modulation of NMDAR function.

Based on these observations, a few powerful, high-throughput approaches are feasible for unbiased phenotyping and screening of drugs targeting NMDARs in neuropsychiatric disorders (Fig. 3).

**Targeting NMDARs for discovery of drugs using human iPSC-derived neurons**

Human NMDARs in situ in iPSC-derived neurons provide an opportunity for their use in drug screening in treating neuropsychiatric disorders. The strategies of drug development on NMDARs are identifying new compounds or repurposed drugs directly targeting NMDARs, or indirectly affecting NMDAR function or signaling pathways downstream of the receptors.

**Targeting NMDARs directly.** Up to now, there has been limited clinical success in drugs directly targeting NMDARs and a few modulators of NMDARs such as memantine and ketamine have been approved by FDA for clinical use despite considerable numbers of filed patents on compounds or drugs related to NMDARs [148]. The primary challenges in the development of drugs directly targeting NMDARs are lack of personalized therapeutics, subtype-selective targeting, and adverse or psychiatric side effects.

As both hyperfunction and hypofunction of NMDARs are implicated in the pathophysiology of epilepsy and ASD [8, 41], a more mechanism-based approach will be advantageous for personalized therapeutics. With the loss of function of NMDAR, the strategy is to enhance NMDAR activity [8]. A recently identified positive allosteric modulator, thienopyrimidinone EU1622-1 restores NMDAR function but does not cause excessive Ca2+ influx and excitotoxicity through increasing agonist potency and channel open probability but diminishing single-channel conductance and calcium permeability [149]. With gain of function of NMDARs, the strategy is to use NMDAR antagonists such as memantine, dextromethorphan, and ketamine to reduce NMDAR activity for avoiding the receptor-mediated excitotoxic brain injury [150].

Subtype-selective targeting of NMDARs has been important to the discovery and development of drugs. Non-subunit selective NMDAR compounds have a broad-spectrum blockade but cause a number of adverse or psychiatric side effects in the mammalian CNS [148, 150]. Thus, NMDAR drug development takes advantage of unique pharmacological properties of the receptor subunits for subtype-selective targeting. In addition, developing NMDAR modulators with low-affinity or partial effects might be a promising strategy because this reduces the psychiatric side effects [150].

Another challenge is to identify drugs discriminatively targeting synaptic and extrasynaptic NMDARs because they have different roles in brain function and in the pathogenesis of neuropsychiatric disorders [6]. An allosteric modulator of NMDARs, EU1794, has bidirectional effects on the receptors, dependent on the concentrations of both glutamate and glycine [151]. EU1794 exhibits a potentiation on NMDARs at a low concentration of glutamate but has an inhibitory effect at a high glutamate concentration. Thus, EU1794 may have the potential to exhibit differential effects on NMDARs between synaptic and non-synaptic sites because of the difference in the concentration.
levels of glutamate, at a high concentration synaptically and at a low concentration extrasynaptically [151].

Targeting NMDAR-associated signaling complexes. NMDARs form a large multiprotein complex through protein-protein interactions and therefore modulating NMDAR function through the interventions of the interactions is a strategy for the discovery and development of drugs that indirectly affect NMDAR function or signaling pathways downstream of the receptors [6, 152, 153]. Here, some of the NMDAR-associated signaling pathways are highlighted as targets for drug screening.

Neuregulin-ErbB4 receptors signaling pathways are implicated in the pathophysiology of schizophrenia [42, 43, 77, 154]. Neuregulin-1 (NRG1), encoded by the schizophrenia candidate gene NRG1, binds to its receptors, ErbB4, and activates the receptors. ErbB4 activation abolishes the increase of NMDAR activity induced by members of the Src family kinases and suppresses long-term potentiation [43, 155, 156]. Members of the Src family kinases regulate human NMDARs in situ in iPSC-derived neurons [32], and therefore Src family kinases as NMDAR-associated signaling complexes could be a target for promising therapeutics in treating neuropsychiatric disorders.

Other proteins, including CaMKII and the postsynaptic density protein PSD-95, interact with NMDARs and may be promising for the translational screening of drugs targeting NMDARs in the treatment of neuropsychiatric disorders. CaMKII, a serine-threonine kinase protein, plays a key role in NMDAR-dependent long-term potentiation and long-term depression [5]. In addition, CaMKII has been implicated in the pathogenesis of various neuropsychiatric disorders [157]. PSD-95, a scaffolding protein, directly interacts with NMDARs to modulate the receptor activity, and could therefore be a potential molecular target in the development and discovery of drugs [6]. Tat-NR2B9c, an interfering peptide, dissociates NMDARs from PSD-95 [158] and improves outcomes after ischemic stroke [159], proving proof of concept that targeting interactions in the NMDAR complex can have therapeutic benefits in humans.

Associated signaling complexes of NMDARs may therefore be promising therapeutic targets for the development and discovery of drugs. Such therapeutics, compared with direct agonists or antagonists of NMDARs, may have mild effects on the receptors per se, thus reducing adverse or psychiatric side effects.

CONCLUSIONS

NMDARs have been implicated in pathophysiology of neuropsychiatric disorders, and therefore modeling NMDAR dysfunction with human iPSC-derived neurons may lead to an unprecedented opportunity to identify novel therapeutic drugs. Efforts to obtain mature human iPSC-derived neurons will make the neurons more broadly applicable for disease modeling. In particular, driving functional expression of NMDARs in human iPSC-derived neurons will contribute to investigations on NMDARs and screening for drugs targeting these receptors, and foster the discovery and development of drugs for treating neuropsychiatric disorders.

REFERENCES

1. Lago SG, Tomasic J, van Rees GF, Steeb H, Cox DA, Rustomi N, et al. Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo. Sci Adv. 2019;5:eaau0903.
2. Wang M, Zhang L, Gage FH. Modeling neuropsychiatric disorders using human induced pluripotent stem cells. Protein Cell. 2020;11:45–59.
3. Willsey AJ, Morris MT, Wang S, Willsey HR, Sun N, Teerkoprij N, et al. The psychiatric cell map initiative: a convergent systems biological approach to illuminating key molecular pathways in neuropsychiatric disorders. Cell. 2018;174:505–20.
4. Barešić A, Nash AJ, Dahoun T, Howes O, Lenhard B. Understanding the genetics of neuropsychiatric disorders: the potential role of genomic regulatory blocks. Mol Psychiatry. 2020;25:6–18.
5. Sohal VS, Rubenstein JLR. Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. Mol Psychiatry. 2019;24:1248–57.
6. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383–400.
7. Myers SJ, Yuan H, Kang QJ, Tan FCK, Traynelis SF, Low CM. Distinct roles of GRIN2A and GRIN2B variants in neurological conditions. F1000Res. 2019;8:F1000.
8. XiangWei W, Jiang Y, Yuan H. De novo mutations and rare variants occurring in NMDA receptors. Curr Opin Pharmacol. 2018;22:37–35.
9. Pankevich DE, Altevogt BM, Dunlop J, Gage FH, Hyman SE. Improving and accelerating drug development for nervous system disorders. Neuron. 2014;84:546–53.
10. Becker RE, Greig NH. Lost in translation: neurophysiologic development and discovery of drugs targeting NMDAR function. Sci Transl Med. 2010;2:61rv66.
11. Berk M. Pathways to new drug discovery in neuropsychiatry. BMC Med. 2012;10:151.
12. Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16:115–30.
13. Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, et al. Induced pluripotent stem cells and their use in human models of disease and development. Physiol Rev. 2019;99:79–114.
14. Haggarty SJ, Perlis RH. Translation: screening for novel therapeutics with disease-relevant cell types derived from human stem cell models. Biol Psychiatry. 2014;75:952–60.
15. Soldner F, Jaenisch R. Medicine. iPSC disease modeling. Science. 2012;338:1155–6.
16. Park IH, Arora N, Hsu H, Maharani N, Ahfeldt T, Shimamura A, et al. Disease-specific induced pluripotent stem cells. Cell 2008;134:877–86.
17. Buxbaum JD, Sklar P. Human induced pluripotent stem cells: a new model for schizophrenia? Cell Stem Cell. 2011;8:461–2.
18. Brennand K, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011;473:221–5.
19. Prilutsky B, Palmer NP, Smedemark-Margulies N, Schlaeger TM, Margulies DM, Kohane IS. iPSC-derived neurons as a higher-throughput readout for autism: promises and pitfalls. Trends Mol Med. 2014;20:91–104.
20. Tidball AM, Parent JM. Concise review: exciting cells: modeling genetic epilepsies with patient-derived induced pluripotent stem cells. Stem Cells (Dayt. Ohio). 2016;34:27–33.
21. Simkin D, Kiskinis E. Modeling pediatric epilepsy through iPSC-based technologies. Epilepsy Curr. 2018;18:240–5.
22. Farkhondeh A, Li R, Gorshkov K, Chen KG, Mith M, Rodems S, et al. Induced pluripotent stem cells for neural drug discovery. Drug Discov Today. 2019;24:992–9.
23. Silva MC, Haggarty SJ. Human pluripotent stem cell-derived models and drug screening in CNS precision medicine. Ann NY Acad Sci. 2020;1471:18–56.
24. Anderson NC, Chen PF, Meganathan K, Afshar Saber W, Petersen AJ, Bhattacharyya A, et al. Balancing serendipity and reproducibility: Pluripotent stem cells as experimental systems for intellectual and developmental disorders. Stem Cell Rep. 2021;16:1446–57.
25. Wainger BJ, Macklin EA, Vucic S, McIlduff CE, Paganoni S, Maragakis NJ, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78:186–96.
26. Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SS, Sandoe J, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2016;7:1–11.
27. Bitar M, Kuiper S, O'Brien EA, Barry G. Genes with human-specific features are primarily involved with brain, immune and metabolic evolution. BMC Bioinform. 2019;20:406–406.
28. Ross PJ, Mok RSF, Smith BS, Rodrigues DC, Mufteev M, Scherer SW, et al. Modeling neuronal consequences of autism-associated gene regulatory variants with human induced pluripotent stem cells. Mol Autism. 2020;11:33.
29. Warming H, Pegasiou CM, Pitera AP, Kariis H, Houghton SD, Kurbatskaya K, et al. A primate-specific short GluN2A-NMDA receptor isoform is expressed in the human brain. Mol Brain. 2019;12:64.
30. Ahfeldt T, Litterman NK, Rubin LL. Studying human disease using human neurons. Brain Res. 2017;1656:40–48.
31. Stein JL, de la Torre-Ubieta L, Tian Y, Parikshak NN, Hernandez IA, Marchetto MC, et al. A quantitative framework to evaluate modeling of cortical development by neural stem cells. Neuron. 2014;83:869–86.
32. Zhang WB, Ross PJ, Tu Y, Wang Y, Beggs S, Sengar AS, et al. Fyn kinase regulates GluN2B subunit-dominant NMDA receptors in human induced pluripotent stem cell-derived neurons. Sci Rep. 2016;6:23837.
1. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2012;486:256.

2. Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR. Autism spectrum disorders and schizophrenia. Transl Psychiatry. 2011;1:e55.

3. Tsavou A, Curtis D. In-silico investigation of coding variants potentially affecting the functioning of the glutamatergic N-methyl-D-aspartate receptor in schizophrenia. Psychiatr Genet. 2019;29:44–50.

4. Yu Y, Lin Y, Takasaki Y, Wang C, Kimura H, Xing J, et al. Rare loss of function mutations in N-methyl-D-aspartate glutamate receptors and their contributions to schizophrenia susceptibility. Transl Psychiatry. 2018;8:12.

5. Javitt DCZS. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301–8.

6. Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR. Autism spectrum disorders and schizophrenia. Transl Psychiatry. 2011;1:e55.

7. Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR. Autism spectrum disorders and schizophrenia. Transl Psychiatry. 2011;1:e55.

8. Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR. Autism spectrum disorders and schizophrenia. Transl Psychiatry. 2011;1:e55.

9. Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR. Autism spectrum disorders and schizophrenia. Transl Psychiatry. 2011;1:e55.
88. Centeno EGZ, Cimarelli R, Bithell A. 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. Mol Neurodegener. 2018;13:37.

89. Klapper SD, Garg P, Dagar S, Lenk K, Gottmann K, Nieweg K. Astrocyte lineage cells are essential for functional neuronal differentiation and synapse maturation in human iPSC-derived neural networks. Glia 2019;67:1893–909.

90. Pedraza S, Wang X, Sasaki SH, Juncos JA, Sejnowski TJ, Simek M, et al. Neuronal network dysfunction in a model for Kleine–Levin syndrome mediated by extracellular matrix protein NMDAR. Nat Commun. 2019;10:4928.

91. Rzhezorzov NM, Connick P, Livesey MR, Borooshad S, Patani R, Burr K, et al. Hypothemic preconditioning reverses Tau ontogenization in human cortical neurons and is mimicked by protein phosphatase 2A inhibition. ElBioMedicine 2016;13:1–41.

92. Salter MW, Kalia LV. Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci. 2018;19:761–78.

93. Yi F, Danko T, Botelho SC, Patzke C, Pak C, Wernig M, et al. Autism-associated SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neural networks. eLife 2016;5:e23788.

94. Shcheglovitov A, Shcheglovitova O, Yazawa M, Portmann T, Shu R, Sebastiano V, et al. SHANK3 and IGF1 restore synaptic depression in human iPSC-derived neurons. Proc Natl Acad Sci USA. 2015;112:E2725–31.

95. Odawara A, Saitoh Y, Alhebshi AH, Gotoh M, Suzuki I. Long-term electrophysiological activity and pharmacological response of human induced pluripotent stem cell-derived neuron and astrocyte co-culture. Biochem Biophys Res Commun. 2014;442:1176–81.

96. Schutte RJ, Xie Y, Ng NN, Figueroas P, Pham AT, O'Dowd DK. Astrocyte-enriched feeder layers from cryopreserved cells support differentiation of spontaneously active networks of human iPSC-derived neurons. J Neurosci Methods. 2018;294:69–79.

97. Yi F, Danko T, Botelho SC, Patske C, Pak C, Wernig M, et al. Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons. Science 2016;352:aaaf2669.

98. Zaslavsky K, Zhang WB, McCready FP, Rodrigues DC, Deneault E, Luo C, et al. SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neural networks. Nat Neurosci. 2018;21:556–64.

99. Yi F, Danko T, Botelho SC, Patzke C, Pak C, Wernig M, et al. Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons. Science 2016;352:aaaf2669.

100. Song L, Wang K, Li Y, Yang Y. Nanotopography promoted neuronal differentiation by BrainPhys medium increases neurons in vitro. Proc Natl Acad Sci USA. 2015;112:E2725–31.

101. Accelerated neuronal and synaptic maturation by BrainPhys medium increases neurons in vitro. Proc Natl Acad Sci USA. 2015;112:E2725–31.

102. Schrode N, Ho SM, Yamamuro K, Dobbyn A, Huckins L, Matos MR, et al. Neuronal medium that supports basic synaptic functions and activity of human induced pluripotent stem cell-derived cortical astrocytes upon iPSC-differentiated cortical neurons. Stem Cell Rep. 2020;2020;13:53–91.

103. Burke EE, Chenoweth JG, Shin JH, Collado-Torres L, Kim SK, Miceli N, et al. Dissecting transcriptomic signatures of neuronal differentiation and maturation using iPSCs. Nat Commun. 2020;11:462.

104. Hoffman GE, Hartley BJ, Flaherty E, Ladran I, Gochman P, Ruderfer DM, et al. Astroglial lineage commitment is concordant with post-mortem adult brains. Nat Commun. 2017;8:2225.
137. Song Z, Yang W, Cheng G, Zhou X, Yang L, Zhao D. Prion protein is essential for the RE1 silencing transcription factor (REST)-dependent developmental switch in synaptic NMDA receptors. Cell Death Dis. 2018;9:541.

138. Corbel C, Hernandez I, Wu B, Kosik KS. Developmental attenuation of N-methyl-D-aspartate receptor subunit expression by microRNAs. Neural Dev. 2015;10:20.

139. Shang Y, Zhang J, Huang EJ. HIPK2-mediated transcriptional control of NMDA receptor subunit expression regulates neuronal survival and cell death. J Neurosci. 2018;38:4006–19.

140. Nicolai J, Burbassi S, Rubin J, Meucci O. CXCL12 inhibits expression of the NMDA receptor’s NR2B subunit through a histone deacetylase-dependent pathway contributing to neuronal survival. Cell Death Dis. 2010;1:e33.

141. Matta JA, Ashby MC, Sanz-Clemente A, Roche KW, Isaac JTR, mGluR5 and NMDA receptors drive the experience- and activity-dependent NMDA receptor NR2B to NR2A subunit switch. Neuron. 2011;70:339–51.

142. Sanz-Clemente A, Matta JA, Isaac JTR, Roche KW. Casein kinase 2 regulates the NR2 subunit composition of synaptic NMDA receptors. Neuron. 2010;67:984–96.

143. Carvajal FJ, Mattison HA, Cerpa W. Role of NMDA receptor-mediated glutamate receptor subunit expression in the RE1 silencing transcription factor (REST)-dependent developmental switch in early postnatal neurons. Cell Stem Cell. 2020;26:108–122.e110.

144. Kirwan P, Turner-Bridger B, Peter M, Momoh A, Arambepola D, Robinson HPC, et al. Circcadian entrainment triggers maturation of human in vitro islets. Cell Death Dis. 2018;9:541.

145. Perszyk R, Katzman BM, Kusumoto H, Kell SA, Epplin MP, Tahirovic YA, et al. An NMDAR positive and negative allosteric modulator series share a binding site — NR1 — NR2B subunit through a histone deacetylase-dependent pathway contributing to neuronal survival. Cereb Cortex. 2020;30:4246–56.

ACKNOWLEDGEMENTS
This work was supported by the Canadian Institutes of Health Research (CIHR) Foundation grant (FDN-154336) to M.W.S., CIHR team grant (EPS-129129) to J.E., CIHR grant (MOP-133423) to J.E. and M.W.S.

AUTHOR CONTRIBUTIONS
W.Z., P.J.R., J.E., and M.W.S. were involved in the conceptualization and writing of the paper.

COMPETING INTERESTS
M.W.S. is a founder, shareholder and Board member of NoNO Inc, which is developing Tat-NR2B9c, now known as nerinetide, as a therapeutic agent. All other authors report no biomedical financial interests or potential conflict of interest.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Michael W. Salter.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

Translated Psychiatry (2022) 12:243